|
Interstitial Lung Disease: Is It In Your Differential?
|
|
Facebook
LinkedIn
E-Mail
|
(3928)
|
Released: 08/04/2023 Expires: 07/31/2024 (subject to change)
- CE for this activity will not be available after this date.
| This activity includes closed captioning. |
Delivery Note: The content for this activity was previously presented during the 2023 AANP National Conference. If you already completed the content of this activity while attending the live or virtual conference, you should not complete this content a second time. Learners should only complete ONE delivery-method to earn credit. Completing multiple delivery options for the same activity is considered duplicate credit for the same content and will not be accepted by regulatory bodies. |
Overview
Interstitial lung diseases (ILD) are a diverse group of lung conditions characterized by inflammation or fibrosis within the lung interstitium which leads to impaired gas exchange. Nurse practitioners need to consider ILD in the differential diagnosis of patients with persistent respiratory problems. Early diagnosis of fibrotic ILD could lead to improved outcomes by intervening sooner in the disease course. A multidisciplinary team is crucial for managing the patient with ILD and the patient is at the center of this team.
Objectives - Differentiate ILD from other pulmonary conditions based on patient history and symptoms.
- Develop a treatment plan for patients with ILD that includes pharmacological and non-pharmacological strategies.
- Summarize the importance of the multidisciplinary team in managing the patient with ILD based on input and preferences from the patient.
- Select components of shared decision-making tactics to utilize in communications with patients with ILD and their caregivers.
- Identify strategies to overcome racial and socioeconomic disparities in the disease course of ILD.
Speakers Jessica Glennie, MSN, APRN Christopher King, MD, FACP, FCCP Jim Kuhn, MA
Disclosure This program was planned in accordance with AANP CE Standards and Policies.The speaker has the following disclosures:
- Jessica Glennie, MSN, APRN has the following disclosures:
- Speaker for Boehringer Ingelheim in clinical area of ILD.
- Speaker for United Therapeutics in clinical area of PH-ILD.
- Christopher King, MD, FACP, FCCP has the following disclosures:
- Speaker/Advisory Boards, United Therapeutics, in clinical area of PH
- Advisory Board, Merck, in clinical area of PH
- Speaker, Altavant, in clinical area of PH
- Jim Kuhn, MA has the following disclosures:
- Member-Speakers Bureau (Volunteer Position), Foundation for Sarcoidosis Research
All Planners involved in this activity have no relevant financial relationships to disclose. This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. This presentation was first presented as a Live event at AANPs 2023 National Conference in New Orleans and recorded for this on-demand presentation. Disclaimer Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions- Read this activity description, including objectives and disclosures.
- Complete the Pretest associated to the activity.
- Complete the educational content:
- Video Presentations: Click the Play button to watch the activity presentation. Full participation credit for the activity will be received once the entire video has been watched.
- Click on the Additional Resources button to review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
- After completing all content, click on the blue Next Steps button:
- Complete the post-test.
- Submit the evaluation to receive full AANP CE/Rx credit.
Additional Information For questions or more information concerning this online CE activity, please visit the AANP Help Center to find answers to frequently asked questions and request assistance.
1.25 Contact Hour(s) of CE, 0.25 of which may be applied towards Pharmacology
|
|
|
|